Asymchem Laboratories (Tianjin) Co., Ltd. (6821.HK)
HKSE · HKD · Healthcare · Biotechnology
HK$108.00 (-5.84%) as of
Key statistics
- Market cap
- 39.09B
- P/E (TTM)
- 28.50
- Forward P/E
- 17.42
- EPS (TTM)
- 3.790
- Dividend yield
- 1.30%
- 52-week range
- 69.200 – 178.000
- Beta
- 0.19
- Revenue (TTM)
- 7.44B
- Profit margin
- 15.93%
- Analyst target
- HK$153.56
- Volume
- 956.00k
About Asymchem Laboratories (Tianjin) Co., Ltd.
Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally. It is involved in small molecule CDMO services for projects covering multiple major disease treatment areas, such as oncology, antiviral, anti-infective, cardiovascular, and diabetes; chemical macromolecule CDMO; biomacromolecule CDMO, including antibody-peptide conjugates; formulation CDMO; clinical CRO; synthetic biology and new technology output business. The company also engages in key pharmaceutical intermediates, APIs, and formulations activities. The company was founded in 1998 and is headquartered in Tianjin, China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Tianjin, China
- Employees
- 10,617
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.